Patent classifications
C12Y303/01001
PURINE ALKALOID-PRODUCING MICROORGANISMS AND METHODS OF MAKING AND USING THE SAME
Provided herein are microorganisms that include one or more heterologous nucleic acid selected from the group of a sequence encoding a 7-methylxanthosine synthase, a sequence encoding a theobromine synthase; and a sequence encoding a caffeine synthase, where the microorganism is capable of producing one or more purine alkaloid in a culture medium, when the microorganism is cultured under conditions sufficient to produce the one or more purine alkaloid. Also provided compositions and kits that include at least one of these microorganisms, and methods of producing one or more purine alkaloid that include culturing one of these microorganisms under conditions sufficient to produce the one or more purine alkaloid.
SECRETAGOGUES DERIVED FROM OXALOBACTER FORMIGENES
The present invention relates to a secretagogue compound derived from oxalate degrading bacteria, for use in the treatment of an oxalate related disease and/or oxalate related imbalance in a subject, wherein the administration of the secretagogue results in a reduction of urinary oxalate and/or plasma oxalate in the subject. The invention further relates to a pharmaceutical composition comprising such a secretagogue compound, a method for treating a subject suffering from an oxalate related disease, and to a method for preparing a secretagogue.
Secretagogues derived from oxalobacter formigenes
The present invention relates to a secretagogue compound derived from oxalate degrading bacteria, for use in the treatment of an oxalate related disease and/or oxalate related imbalance in a subject, wherein the administration of the secretagogue results in a reduction of urinary oxalate and/or plasma oxalate in the subject. The invention further relates to a pharmaceutical composition comprising such a secretagogue compound, a method for treating a subject suffering from an oxalate related disease, and to a method for preparing a secretagogue.
Purine alkaloid-producing microorganisms and methods of making and using the same
Provided herein are microorganisms that include one or more heterologous nucleic acid selected from the group of a sequence encoding a 7-methylxanthosine synthase, a sequence encoding a theobromine synthase; and a sequence encoding a caffeine synthase, where the microorganism is capable of producing one or more purine alkaloid in a culture medium, when the microorganism is cultured under conditions sufficient to produce the one or more purine alkaloid. Also provided compositions and kits that include at least one of these microorganisms, and methods of producing one or more purine alkaloid that include culturing one of these microorganisms under conditions sufficient to produce the one or more purine alkaloid.
Method for producing objective substance
A method for producing an objective substance such as vanillin and vanillic acid is provided. An objective substance is produced from a carbon source or a precursor of the objective substance by using a microorganism having an objective substance-producing ability, which microorganism has been modified so that the activity of S-adenosyl-L-homocysteine hydrolase is increased.
Method for Producing Objective Substance
A method for producing an objective substance such as vanillin and vanillic acid is provided. An objective substance is produced from a carbon source or a precursor of the objective substance by using a microorganism having an objective substance-producing ability, which microorganism has been modified so that the activity of S-adenosyl-L-homocysteine hydrolase is increased.
SECRETAGOGUES DERIVED FROM OXALOBACTER FORMIGENES
The present invention relates to a secretagogue compound derived from oxalate degrading bacteria, for use in the treatment of an oxalate related disease and/or oxalate related imbalance in a subject, wherein the administration of the secretagogue results in a reduction of urinary oxalate and/or plasma oxalate in the subject. The invention further relates to a pharmaceutical composition comprising such a secretagogue compound, a method for treating a subject suffering from an oxalate related disease, and to a method for preparing a secretagogue.
Secretagogues derived from oxalobacter formigenes
The present invention relates to a secretagogue compound derived from oxalate degrading bacteria, for use in the treatment of an oxalate related disease and/or oxalate related imbalance in a subject, wherein the administration of the secretagogue results in a reduction of urinary oxalate and/or plasma oxalate in the subject. The invention further relates to a pharmaceutical composition comprising such a secretagogue compound, a method for treating a subject suffering from an oxalate related disease, and to a method for preparing a secretagogue.
GENETICALLY ENGINEERED BACTERIUM USING GLUCOSE AS SUBSTRATE FOR DE NOVO SYNTHESIS OF VANILLIN AND APPLICATION THEREOF
The present invention discloses a genetically engineered bacterium using glucose as a substrate for de novo synthesis of vanillin and an application thereof, which belongs to the technical field of gene recombination and metabolic engineering. The genetically engineered bacterium using the glucose as the substrate for de novo synthesis of vanillin disclosed by the present invention is recombinant Corynebacterium glutamicum modified by chassis microorganisms and including a vanillin synthesis module and a methyl cyclic regeneration module. The genetically engineered bacteria constructed by the present invention are safe and non-toxic, can use the glucose for de novo synthesis of natural vanillin, and is low in production cost, high in yield, and promising in application prospect.
ZEA MAYS REGULATORY ELEMENTS AND USES THEREOF
Provided are constructs and methods for expressing a transgene in plant cells and/or plant tissues using Zea mays GRMZM2G015295 gene regulatory elements.